Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Synth supergroup

How Senti’s synthetic biology platforms could improve cell, gene therapies

February 27, 2018 12:33 PM UTC

With a $53 million series A announced on Tuesday, Senti Biosciences Inc. is combining synthetic biology platform technologies from more than five institutions to build an immunotherapy pipeline and a partnering engine. The company believes its engineered biological circuits will generate adaptive cell and gene therapies with controlled responses to environmental cues.

Synthetic biology circuits incorporate two or more artificial components into cells, typically encoded in DNA, to carry out novel functions. Senti is developing circuits to control when, where and how potently cell and gene therapies exert their effects in vivo...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article